Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec 15;128(24):2747-2748.
doi: 10.1182/blood-2016-11-745323.

Measure for measure: minimal residual disease in CLL

Richard F Little  1 , Lisa M McShane  1
Affiliations
Comment

Measure for measure: minimal residual disease in CLL

Richard F Little et al. Blood. .

Abstract

In this issue of Blood, Kwok and colleagues have provided a wealth of retrospective clinical data that greatly expands our appreciation for the prognostic importance of flow-cytometric residual disease measurement across a spectrum of clinical presentations in chronic lymphocytic leukemia (CLL).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Comment on

References

    1. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128(24):2770-2773. - PubMed
    1. Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107(11):4563-4569. - PubMed
    1. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988. - PubMed
    1. Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group (published online ahead of print 29 August 2016). J Clin Oncol. 2016. - PubMed
    1. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279-286. - PMC - PubMed